Abstracts tagged "Cardiovascular disease"

Abstract Number: 1390 • 2014 ACR/ARHP Annual Meeting
Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries – Implications for CV Risk Assessment
Atacc-RA Collaborative Group, Division of Rheumatology, Mayo Clinic, Rochester, MN; Diakonhjemmet hospital, Oslo, Norway; Dudley Group NHS Foundation Trust, West Midlands, United Kingdom; Radboud University Medical Center, Nijmegen, Netherlands; University of Umeå, Umeå, Sweden; University of Athens, Athens, Greece; Harbor UCLA Medical Center, Torrance, CA; Harvard Medical School Brigham and Women's Hospital, Boston, MA; Hospital Universitario Marques de Valdecilla, Santander, Spain; School of Physiology, Faculty of Health Sciences, Witwatersrand University, Johannesburg, South Africa; University of Manitoba, Winnipeg, MB, Canada; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubir, México City, Mexico; Hospital Medisch Spectrum Twente, Enschede, Netherlands
Background/Purpose Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease (CVD). CVD risk scores for the general population do not accurately predict…
Abstract Number: 842 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Jie Zhang¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Huifeng Yun⁵, Paul M. Muntner⁶, Emily Levitan⁶, Monica Safford⁷, Kenneth G. Saag⁸, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁷, ¹Ryals Soph Bldg., Rm. 517b, Univ. of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recently cholesterol treatment guidelines recommend that diabetes (DM) should be considered a CVD risk equivalent to a history of coronary heart disease (CHD). Despite…
Abstract Number: 341 • 2014 ACR/ARHP Annual Meeting
Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Jessica O Williams¹, Eddie C.Y. Wang², Derek Lang¹ and Anwen S. Williams², ¹Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Increased cardiovascular (CV) risk is prevalent in several forms of inflammatory arthritides. The mechanisms that regulate CV disease during early inflammatory arthritis are ill-defined.…
Abstract Number: 2641 • 2014 ACR/ARHP Annual Meeting
Cardiac Magnetic Resonance Imaging in Systemic Lupus Erythematosus
Alexa Meara¹, Namrata Dhillon², Kimberly Fisher³, Paul Jensen⁴ and Stacy P. Ardoin⁵, ¹Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Internal Medicine/Pediatrics, The Ohio State University, Nationwide Children's Hospital, Columbus, OH, ⁵Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH
Background/Purpose Cardiac complications of SLE are common and include both acute and chronic manifestations: pericarditis, myocarditis, valvular disease, pulmonary hypertension, atherosclerosis, ischemic and non-ischemic cardiomyopathy. …
Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Alper van Sijl¹, Mamas Mamas², Mark Lunt^3,4, . BSRBR Control Centre Consortium³, Kath Watson⁵, Deborah P. Symmons^3,6 and Kimme L. Hyrich⁷, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…
Abstract Number: 1400 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies
Michelle Avina¹, Sally Choi², Sharan Rai³, Hyon K. Choi⁴ and Mary De Vera^3,5, ¹Faculty of Sciences, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Boston University School of Medicine, Boston, MA, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common vascular event after myocardial infarction…
Abstract Number: 841 • 2014 ACR/ARHP Annual Meeting
Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
J An¹, E Alemao², K Reynolds³, H Kawabata², D H Solomon⁴, K P Liao⁴ and T C Cheetham³, ¹Western University of Health Sciences, Pomona, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Kaiser Permanente Southern California, Pasadena, CA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Lipid levels are known to be lower in patients with RA compared with the general population; however, differences in cardiovascular (CV) risk associated with…
Abstract Number: 337 • 2014 ACR/ARHP Annual Meeting
Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis
Perle Totoson¹, Katy Maguin-Gaté¹, Daniel Wendling² and Céline Demougeot¹, ¹EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose Growing evidence indicate that Rheumatoid Arthritis (RA)-associated increase in cardiovascular risk is secondary to the presence of endothelial dysfunction (ED). Although Tumor Necrosis Factor…
Abstract Number: 2459 • 2014 ACR/ARHP Annual Meeting
Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis
Fernanda Genre¹, Raquel López-Mejías¹, Mercedes García-Bermúdez², Santos Castañeda³, Carlos González-Juanatey⁴, Javier Llorca⁵, Alfonso Corrales¹, Begoña Ubilla¹, Jose A. Miranda-Filloy⁶, Encarnación Amigo⁶, Trinitario Pina Murcia¹, Carmen Gómez-Vaquero⁷, Luis Rodriguez-Rodriguez⁸, Benjamin Fernández Gutierrez⁸, Alejandro Balsa⁹, Dora Pascual-Salcedo⁹, Francisco Javier López-Longo¹⁰, Patricia Carreira¹¹, Ricardo Blanco¹², Isidoro González-Alvaro¹³, Javier Martin¹⁴ and Miguel A González-Gay¹, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Universitario Lucus Augusti, Rheumatology Division, Lugo, Spain, ⁷Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁸Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ⁹Hospital Universitario La Paz, Department of Rheumatology, Madrid, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ¹¹Hospital Universitario 12 de Octubre, Department of Rheumatology, Madrid, Spain, ¹²Hospital Marques de Valdecilla, Santander, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain
Background/Purpose: Rheumatoid arthritis is an inflammatory disease with a high incidence of cardiovascular disease due to accelerated atherosclerosis. Osteoprotegerin (OPG) has been associated with an…
Abstract Number: 1852 • 2014 ACR/ARHP Annual Meeting
Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Katelynn Wilton¹, Floranne C. Ernste², Cynthia S. Crowson³, Eric L. Matteson⁴, Hilal Maradit Kremers⁵ and Marta Sánchez-Menéndez⁶, ¹Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Centro Medico de Asturias, Oviedo, Spain
Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although…
Abstract Number: 1376 • 2014 ACR/ARHP Annual Meeting
Angiographic Pattern Among Rheumatoid Arthritis Patients Who Are Hospitalized Due to Acute Coronary Syndrome
Marie Holmqvist¹, Ängla Mantel², Tomas Jernberg³, Stefan James⁴, Solveig Wållberg-Jonsson⁵ and Johan Askling⁶, ¹Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ²Dept of Medicine, Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, ³Department of medicine, Section of Cardiology, Karolinska University Hospital, Stockholm, Sweden, ⁴3Department of Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden, ⁵Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁶Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: We aimed at investigating and to compare the angiographic pattern of stenoses in patients with rheumatoid arthritis (RA) and general population comparators hospitalized due…
Abstract Number: 829 • 2014 ACR/ARHP Annual Meeting
Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome
Mariano Andrés¹, María Amparo Quintanilla², Francisca Sivera¹, Paloma Vela^3,4 and Juan Miguel Ruiz-Nodar⁵, ¹Sección de Reumatología, Hospital General Universitario de Elda, Alicante, Spain, ²Sección de Cardiología, Hospital General Universitario de Elda, Alicante, Spain, ³Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ⁴Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵Servicio de Cardiología, Hospital General Universitario de Alicante, Alicante, Spain
Background/Purpose: Increased cardiovascular (CV) risk in gout relates to crystal-driven inflammation. Monosodium urate (MSU) crystals are found in ~25% of patients with asymptomatic hyperuricemia (AH)…
Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Svetlana Krasnokutsky¹, Robert T. Keenan², Laura Schneck¹, Craig Tenner³, Helene Strauss⁴, Daria Crittenden⁵, Aaron Lehmann¹ and Michael H. Pillinger¹, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Duke University, Durham, NC, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Amgen, Thousand Oaks, CA
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…
Abstract Number: 2461 • 2014 ACR/ARHP Annual Meeting
Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis
Raquel López-Mejías¹, Begoña Ubilla¹, Fernanda Genre¹, Alfonso Corrales¹, José L Hernandez², Ivan Ferraz-Amaro³, Linda Tsang⁴, Javier Llorca⁵, Ricardo Blanco⁶, Carlos González-Juanatey⁷, MA González-Gay^1,4 and Patrick H Dessein⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ²Department of Internal Medicine, Hospital Universitario Marques de Valdecilla, University of Cantabria, RETICEF, IDIVAL, Santander, Spain, ³Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ⁴Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Hospital Universitario Lucus Augusti. Cardiology Division, Lugo, Spain
Background/Purpose: We determined whether osteoprotegerin (OPG) concentrations are associated with established cardiovascular disease (CVD) amongst patients with rheumatoid arthritis (RA). Methods: OPG concentrations were measured…
Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri¹, Natasha Dehghan², Eric C. Sayre³, Kamran Shojania¹ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA). We assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].